| Ytd | 92.61% | |
| 1y | 320.57% |
| Open | 14.00 | Prev Close | 14.15 | Low | 13.27 | High | 14.13 | Mkt Cap | 1.79B |
| Vol | 4.74M | Avg Vol | 4.36M | EPS | -3.14 | P/E | N/A | Forward P/E | -13.39 |
| Beta | 2.51 | Short Ratio | 2.07 | Inst. Own | 72.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 11.25 | 200-d Avg | 7.54 | 1yr Est | 22.33 |
Canaccord Genuity analyst Sumant Kulkarni maintains Compass Pathways (NASDAQ:CMPS) with a Buy and
Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial opera